Search Medical Condition
Please enter condition
Please choose location from dropdown

Nerima-ku, Japan Clinical Trials

A listing of Nerima-ku, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (454) clinical trials

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

This is a Phase I/Ib, multi-center, open-label study to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of LHC165 single agent and in combination with the Programmed Cell Death Protein-1 (PD-1) checkpoint inhibitor PDR001. Two different dosing schedules will be explored for LHC165 single agent and ...

Phase

8.35 miles

Learn More »

Study of BAY1834942 in Patients With Solid Tumors

The primary objectives of the study are to evaluate and characterize the tolerability and safety profile of repeated doses of BAY1834942 alone or in combination with pembrolizumab, and to characterize the pharmacokinetics of BAY1834942 alone or in combination with pembrolizumab after single dose. Secondary objectives are to evaluate the tumor ...

Phase

8.35 miles

Learn More »

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.

Phase

8.35 miles

Learn More »

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Phase

8.35 miles

Learn More »

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Phase

8.35 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of JNJ-63723283 an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).

Phase

8.35 miles

Learn More »

A Study of LY3415244 in Participants With Advanced Solid Tumors

The goal of this study is to evaluate the safety of LY3415244 administered as monotherapy to participants with advanced solid tumors.

Phase

8.35 miles

Learn More »

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Phase

8.35 miles

Learn More »

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Patients who complete definitive treatment with SoC SBRT and are confirmed to meet all eligibility criteria will be randomized 1:1 to durvalumab or placebo. The primary objective of this study is to assess the efficacy of durvalumab monotherapy compared to placebo in terms of PFS. Key secondary is to assess ...

Phase

8.35 miles

Learn More »

Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with ABBV-181 as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with ABBV-181. The study will consist of 2 phases: dose escalation and ...

Phase

8.35 miles

Learn More »